Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
- 1 March 2007
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (3) , 323-341
- https://doi.org/10.4065/82.3.323
Abstract
No abstract availableKeywords
This publication has 182 references indexed in Scilit:
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Laboratory correlates in multiple myeloma: how useful for prognosis?Blood Reviews, 2001
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979